CRSP
CRISPR Therapeutics AGCompany Information
- Company Name
- CRISPR Therapeutics AG
- CIK
- CIK0001674416
- Category
- Large accelerated filer
- Ticker: Exchange
- CRSP: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- CRSP
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-08-06
- Last sale
- 2026-09-22
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 284,155
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 74,509,886
- Shares outstanding
- 96,514,102
- Ownership
- 77.20%
Earnings Market Reaction
- Filing date
- 2026-08-03
- Price on filing date
- —
- 1-month reaction
- 16.44%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 291 | 423 | 348 | 286 | 194 | 235 | 298 | 226 | 484 | 707 | 389 | 528 | ||||||
| Marketable Securities Current | 2,073 | 2,018 | 1,628 | 1,629 | 1,528 | 1,620 | 1,606 | 1,710 | 1,517 | 1,401 | 1,304 | 1,212 | ||||||
| Accounts Receivable Net Current | - | - | 0 | 0 | 0 | 0 | 25 | 0 | 0 | 0 | 200 | - | ||||||
| Prepaid Expense And Other Assets Current | 7 | 7 | 10 | 13 | 12 | 12 | 8 | 8 | 9 | 11 | 14 | 21 | ||||||
| Assets Current | 2,372 | 2,448 | 1,986 | 1,929 | 1,734 | 1,868 | 1,937 | 1,944 | 2,010 | 2,120 | 1,908 | 1,761 | ||||||
| Property Plant And Equipment Net | 108 | 112 | 116 | 121 | 125 | 129 | 134 | 139 | 143 | 147 | 152 | 156 | ||||||
| Restricted Cash Noncurrent | 8 | 8 | 8 | 8 | 8 | 8 | 12 | 12 | 12 | 12 | 12 | 12 | ||||||
| Marketable Securities Noncurrent | - | 0 | 0 | 28 | - | - | 0 | 0 | 11 | 0 | 2 | 0 | ||||||
| Operating Lease Right Of Use Asset | 126 | 129 | 132 | 135 | 138 | 140 | 143 | 146 | 149 | 151 | 154 | 156 | ||||||
| Finite Lived Intangible Assets Net | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 38 | 29 | 24 | 24 | 25 | 21 | 16 | 16 | 15 | 9 | 2 | 2 | ||||||
| Assets | 2,651 | 2,726 | 2,265 | 2,245 | 2,030 | 2,166 | 2,242 | 2,256 | 2,340 | 2,439 | 2,230 | 2,087 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 11 | 14 | 11 | 12 | 10 | 13 | 15 | 16 | 9 | 16 | 38 | 26 | ||||||
| Accrued Liabilities Current | 70 | 75 | 89 | 84 | 74 | 85 | 41 | 47 | 92 | 76 | 45 | 66 | ||||||
| Contract With Customer Liability Current | 15 | 15 | 16 | 1 | 2 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | ||||||
| Taxes Payable Current | 0 | 1 | 1 | 3 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | ||||||
| Operating Lease Liability Current | 19 | 19 | 19 | 18 | 18 | 18 | 17 | 17 | 16 | 16 | 16 | 15 | ||||||
| Other Liabilities Current | 17 | 13 | 13 | 0 | 0 | 0 | 10 | 5 | 5 | 5 | 5 | 0 | ||||||
| Liabilities Current | 133 | 136 | 149 | 119 | 104 | 119 | 88 | 90 | 128 | 119 | 109 | 111 | ||||||
| Contract With Customer Liability Noncurrent | - | - | 0 | 12 | 12 | 12 | 12 | 12 | 13 | 14 | 14 | 16 | ||||||
| Long Term Debt | 586 | 585 | - | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 179 | 184 | 188 | 193 | 197 | 202 | 206 | 211 | 215 | 219 | 223 | 227 | ||||||
| Other Liabilities Noncurrent | 6 | 6 | 6 | 5 | 4 | 3 | 3 | 4 | 4 | 4 | 1 | 5 | ||||||
| Liabilities | 904 | 911 | 343 | 329 | 319 | 337 | 310 | 316 | 359 | 355 | 347 | 359 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | ||||||
| Treasury Stock Value | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Additional Paid In Capital Common Stock | 3,910 | 3,884 | 3,862 | 3,725 | 3,415 | 3,324 | 3,294 | 3,255 | 3,224 | 3,199 | 2,878 | 2,821 | ||||||
| Retained Earnings Accumulated Deficit | -2,162 | -2,070 | -1,948 | -1,817 | -1,710 | -1,502 | -1,366 | -1,329 | -1,243 | -1,116 | -1,000 | -1,089 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -5 | -2 | 5 | 5 | 4 | 4 | 2 | 11 | -3 | -2 | 2 | -7 | ||||||
| Stockholders Equity | 1,747 | 1,815 | 1,922 | 1,916 | 1,711 | 1,829 | 1,932 | 1,940 | 1,981 | 2,084 | 1,883 | 1,728 | ||||||
| Liabilities And Stockholders Equity | 2,651 | 2,726 | 2,265 | 2,245 | 2,030 | 2,166 | 2,242 | 2,256 | 2,340 | 2,439 | 2,230 | 2,087 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 71.50 | 0.03 | 0.03 | ||||||
| Common Stock Shares Authorized | 144 | 132 | 132 | 132 | 132 | 132 | 132 | 132 | 132 | 130 | 127 | - | ||||||
| Common Stock Shares Issued | 97 | 97 | 96 | 94 | 89 | 87 | 86 | 86 | 85 | 85 | 80 | 80 | ||||||
| Shares Outstanding | 97 | 96 | 96 | 94 | 88 | 86 | 86 | 85 | 85 | 85 | 80 | 79 | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCRISPR Therapeutics AG (CRSP) — SEC Financial Statements & Analysis
CRISPR Therapeutics AG (CRSP) is a biological products, (no diagnostic substances) company, incorporated in V8. CRISPR Therapeutics AG trades on Nasdaq as: CRSP. CRISPR Therapeutics AG (CRSP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-03. Based on that filing, CRISPR Therapeutics AG carries a market cap of $5.26B, a P/E ratio of -11.67x, a P/B ratio of 3.01x, a P/S ratio of 393.06x, an enterprise value of $5.56B, and an EV/EBITDA multiple of -10.78x. On profitability, it posts an operating margin of -3989.99%, a net margin of -3368.72%, a Return on Equity (ROE) of -26.09%, a Return on Assets (ROA) of -19.28%, and a Return on Invested Capital (ROIC) of -30.02%. Per share, it reports EPS of $-4.67, diluted EPS of $-4.67, free cash flow per share of $-3.85, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -64.80% year-over-year, net income growth of -3.56% year-over-year, and EPS growth of -13.00% year-over-year. On the balance sheet, it maintains a current ratio of 17.85x, a quick ratio of 17.79x, working capital of $2.24B, a debt-to-equity ratio of 0.52x, a debt ratio of 0.34, free cash flow of $-371.32M (TTM), and net debt of $294.86M. Figures sourced from SEC EDGAR.
- Market Cap
- $5.26B
- P/E TTM
- -11.67x
- EPS TTM
- $-4.67
- P/B TTM
- 3.01x
- ROE TTM
- -26.09%
- ROA TTM
- -19.28%
- Debt To Equity
- 0.52x
- Free Cash Flow TTM
- $-371.32M
- Net Revenue TTM Growth 1Y
- -64.80%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is CRISPR Therapeutics AG in?
CRISPR Therapeutics AG (CRSP) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does CRSP trade on?
CRISPR Therapeutics AG (CRSP) trades on the Nasdaq.
Where is CRISPR Therapeutics AG incorporated?
CRISPR Therapeutics AG is incorporated in Switzerland.
When was CRISPR Therapeutics AG (CRSP)'s most recent SEC filing?
CRISPR Therapeutics AG (CRSP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-03.
What is CRSP's market cap?
CRISPR Therapeutics AG (CRSP) has a market capitalization of $5.26B as of 2026-06-30.
What is CRSP's EPS (earnings per share)?
CRISPR Therapeutics AG (CRSP)'s trailing twelve month EPS is $-4.67 as of 2026-06-30.
What is CRSP's ROE (return on equity)?
CRISPR Therapeutics AG (CRSP)'s trailing twelve month Return on Equity (ROE) is -26.09% as of 2026-06-30.
What is CRSP's ROA (return on assets)?
CRISPR Therapeutics AG (CRSP)'s trailing twelve month Return on Assets (ROA) is -19.28% as of 2026-06-30.
What is CRSP's ROIC (return on invested capital)?
CRISPR Therapeutics AG (CRSP)'s trailing twelve month Return on Invested Capital (ROIC) is -30.02% as of 2026-06-30.
What is CRSP's EV/EBITDA?
CRISPR Therapeutics AG (CRSP)'s trailing twelve month EV/EBITDA is -10.78x as of 2026-06-30.